Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

AVTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.25%

Insider Buying (Last 12 Months): $6,250.00

Insider Selling (Last 12 Months): $0.00

Avalo Therapeutics Insider Trading History Chart

Avalo Therapeutics Share Price & Price History

^$13.48

▲ +0.08 (0.60%)

As of 11/14/2024 01:00 AM ET

Days: 30 | 90 | 365

Nvidia’s world of pain awaits

From Porter & Company | Ad

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Click play to stream The Final Frontier at no cost

Avalo Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/12/2024	June Sherie Almenoff	Director	Buy	500	$12.50	$6,250.00	500
6/26/2023	Armistice Capital, Llc	Major Shareholder	Sell	11,442	$146.40	$1,675,108.80	6,953
6/20/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	8	$993.60	$7,948.80	5,940
6/16/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	12	$936.00	$11,232.00	5,932
6/14/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	25	$835.20	$20,880.00	5,906
6/12/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	8	$1,041.60	$8,332.80	5,844
6/9/2023	Christopher Ryan Sullivan	CFO	Buy	2	$820.80	$1,641.60	5
6/9/2023	Garry Arthur Neil	CEO	Buy	16	$820.80	$13,132.80	55
5/30/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	2	$688.80	$1,377.60	5,772
5/25/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	8	$664.80	$5,318.40	5,769
5/22/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	29	$801.60	$23,246.40	5,723
5/18/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	54	$789.60	$42,638.40	5,667
5/15/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	7	$612.00	$4,284.00	5,611
5/12/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	9	$588.00	$5,292.00	5,604
5/8/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	20	$628.80	$12,576.00	5,594
5/4/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	62	$669.60	$41,515.20	5,552
4/26/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	1	$712.80	$712.80	5,484
4/24/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	52	$734.40	$38,188.80	5,459
4/20/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	20	$739.20	$14,784.00	5,407
4/17/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	62	$710.40	$44,044.80	5,344
4/10/2023	Caissa Capital Management Ltd.	Major Shareholder	Buy	130	$547.20	$71,136.00	5,177
12/9/2022	Garry Arthur Neil	CEO	Buy	8	$1,060.80	$8,486.40	38
3/14/2022	Armistice Capital, Llc	Director	Buy	416	$156.00	$64,896.00
3/10/2022	Armistice Capital, Llc	Director	Buy	108	$168.00	$18,144.00
3/7/2022	Armistice Capital, Llc	Director	Buy	1,354	$158.40	$214,473.60
3/3/2022	Armistice Capital, Llc	Director	Buy	208	$170.40	$35,443.20
2/24/2022	Armistice Capital, Llc	Director	Buy	416	$192.00	$79,872.00
2/22/2022	Armistice Capital, Llc	Director	Buy	345	$184.80	$63,756.00
2/17/2022	Armistice Capital, Llc	Director	Buy	625	$194.40	$121,500.00
1/20/2022	Armistice Capital, Llc	Director	Buy	50	$204.00	$10,200.00
1/18/2022	Armistice Capital, Llc	Director	Buy	859	$211.20	$181,420.80
1/14/2022	Armistice Capital, Llc	Director	Buy	354	$223.20	$79,012.80
1/12/2022	Armistice Capital, Llc	Director	Buy	238	$249.60	$59,404.80
1/10/2022	Armistice Capital, Llc	Director	Buy	2,046	$237.60	$486,129.60
1/7/2022	Armistice Capital, Llc	Director	Buy	574	$249.60	$143,270.40
12/10/2021	Christopher Ryan Sullivan	CAO	Buy	3	$376.80	$1,130.40
12/10/2021	H. Jeffrey Wilkins	Insider	Buy	26	$376.80	$9,796.80
12/10/2021	Schond L. Greenway	CFO	Buy	9	$376.80	$3,391.20

Nvidia’s world of pain awaits

From Porter & Company | Ad

Click play to stream The Final Frontier at no cost

SEC Filings (Institutional Ownership Changes) for Avalo Therapeutics (NASDAQ:AVTX)

87.06% of Avalo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Avalo Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/27/2024	Logos Global Management LP	539,079	$6.72M	0.5%	N/A	52.135%
8/15/2024	Affinity Asset Advisors LLC	45,000	$0.56M	0.1%	+350.0%	4.352%
5/17/2024	Ikarian Capital LLC	46,648	$1.02M	0.1%	N/A	4.511%
5/15/2024	Affinity Asset Advisors LLC	10,000	$0.22M	0.0%	N/A	0.971%
5/14/2024	Natixis	2,512	$55K	0.0%	-45.4%	0.244%
11/13/2023	Acadian Asset Management LLC	283,306	$34K	0.0%	N/A	1.399%
8/11/2023	VR Adviser LLC	1,250,000	$0.44M	0.1%	+25.0%	6.173%
5/16/2023	Great Point Partners LLC	474,639	$0.83M	0.2%	N/A	3.595%
5/5/2023	Monashee Investment Management LLC	60,000	$0.11M	0.0%	N/A	0.455%
2/15/2023	Nantahala Capital Management LLC	540,667	$2.73M	0.2%	-1.3%	5.746%
11/14/2022	Armistice Capital LLC	3,964,666	$13.16M	0.2%	-91.7%	42.115%
11/14/2022	Point72 Asset Management L.P.	500,737	$1.66M	0.0%	-91.7%	5.319%
11/10/2022	Nantahala Capital Management LLC	547,814	$1.82M	0.1%	-91.8%	5.819%
10/27/2022	Assenagon Asset Management S.A.	15,646	$52K	0.0%	N/A	0.166%
8/15/2022	Nantahala Capital Management LLC	6,710,327	$3.36M	0.2%	-2.0%	71.280%
8/15/2022	Opaleye Management Inc.	450,000	$0.23M	0.1%	-69.1%	4.780%
5/12/2022	Integral Health Asset Management LLC	700,000	$0.51M	0.1%	-56.9%	0.621%
5/3/2022	Leo Brokerage LLC	62,629	$45K	0.0%	N/A	0.056%
4/25/2022	Assenagon Asset Management S.A.	42,338	$31K	0.0%	-92.7%	0.038%
2/15/2022	Stonepine Capital Management LLC	1,510,095	$2.57M	1.2%	+77.7%	1.344%
2/15/2022	LGL Partners LLC	28,850	$49K	0.0%	N/A	0.026%
2/14/2022	Freestone Capital Holdings LLC	20,000	$34K	0.0%	N/A	0.018%
2/14/2022	Soleus Capital Management L.P.	770,000	$1.31M	0.1%	N/A	0.686%
2/8/2022	Northern Trust Corp	533,578	$0.91M	0.0%	+3.1%	0.475%
2/1/2022	Assenagon Asset Management S.A.	582,718	$0.99M	0.0%	-33.7%	0.519%
1/24/2022	Strs Ohio	38,400	$65K	0.0%	-40.2%	0.034%
1/20/2022	Minot Wealth Management LLC	34,645	$59K	0.0%	-66.5%	0.031%
12/29/2021	Hudson Bay Capital Management LP	197,133	$0.43M	0.0%	N/A	0.176%
11/16/2021	Opaleye Management Inc.	1,459,400	$3.18M	0.6%	N/A	1.299%
11/16/2021	Squarepoint Ops LLC	18,657	$41K	0.0%	N/A	0.017%
11/16/2021	Two Sigma Advisers LP	801,300	$1.75M	0.0%	N/A	0.713%
11/16/2021	Two Sigma Investments LP	732,931	$1.60M	0.0%	N/A	0.653%
11/16/2021	Laurion Capital Management LP	330,444	$0.72M	0.0%	N/A	0.294%
11/15/2021	Point72 Asset Management L.P.	6,008,850	$13.10M	0.1%	N/A	5.350%
11/15/2021	Atom Investors LP	27,507	$60K	0.0%	N/A	0.024%
11/15/2021	Voya Investment Management LLC	21,854	$48K	0.0%	N/A	0.019%
11/15/2021	Caas Capital Management LP	11,812	$26K	0.0%	N/A	0.011%
11/12/2021	Aristides Capital LLC	48,953	$0.11M	0.0%	N/A	0.044%
11/12/2021	Stonepine Capital Management LLC	850,000	$1.85M	0.8%	N/A	0.770%
11/12/2021	Geode Capital Management LLC	1,242,382	$2.71M	0.0%	N/A	1.126%
11/12/2021	Integral Health Asset Management LLC	1,625,000	$3.54M	1.0%	N/A	1.473%
11/10/2021	Goldman Sachs Group Inc.	672,664	$1.47M	0.0%	N/A	0.610%
11/10/2021	Creative Planning	14,814	$32K	0.0%	N/A	0.013%
11/10/2021	Alliancebernstein L.P.	19,100	$42K	0.0%	N/A	0.017%
11/9/2021	BlackRock Inc.	3,716,943	$8.10M	0.0%	N/A	3.369%
11/9/2021	Monashee Investment Management LLC	270,000	$0.59M	0.1%	N/A	0.245%
11/8/2021	Meeder Asset Management Inc.	19,260	$43K	0.0%	N/A	0.017%
11/4/2021	Asymmetry Capital Management L.P.	534,621	$1.17M	0.7%	N/A	0.485%
11/4/2021	Deutsche Bank AG	31,794	$69K	0.0%	N/A	0.029%
11/2/2021	Cambridge Investment Research Advisors Inc.	12,164	$27K	0.0%	N/A	0.011%
11/2/2021	New York State Common Retirement Fund	22,214	$48K	0.0%	N/A	0.020%
11/2/2021	Victory Capital Management Inc.	15,788	$34K	0.0%	N/A	0.014%
11/1/2021	SG Americas Securities LLC	18,596	$41K	0.0%	N/A	0.017%
10/29/2021	Commonwealth Equity Services LLC	52,000	$0.11M	0.0%	N/A	0.047%
10/25/2021	Minot Wealth Management LLC	103,410	$0.23M	0.0%	N/A	0.094%
10/22/2021	Strs Ohio	64,200	$0.14M	0.0%	N/A	0.058%
10/19/2021	Assenagon Asset Management S.A.	879,334	$1.92M	0.0%	N/A	0.797%
10/19/2021	Tamar Securities LLC	23,084	$50K	0.0%	N/A	0.021%

Data available starting January 2016

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Today's Range

Now: $13.48

$12.78

$13.59

50 Day Range

MA: $10.64

$7.70

$14.44

52 Week Range

Now: $13.48

$3.95

$34.46

Volume

55,077 shs

Average Volume

214,778 shs

Market Capitalization

$13.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Who are the company insiders with the largest holdings of Avalo Therapeutics?: Avalo Therapeutics' top insider shareholders include:
Armistice Capital, Llc (Major Shareholder)
Caissa Capital Management Ltd (Major Shareholder)
June Sherie Almenoff (Director)
Garry Arthur Neil (CEO)
Christopher Ryan Sullivan (CFO)
Learn More about top insider investors at Avalo Therapeutics.